Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of BIO-008 Injection for Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity in Patients With Advanced Solid Tumors

NCT06027346 is registered in ClinicalTrials.gov with Shijiazhuang Yiling Pharmaceutical Co. Ltd as lead sponsor.

NCT NCT06027346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06027346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of BIO-008 Injection for Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity in Patients With Advanced Solid Tumors
Lead sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
July 17, 2023
Completion date
May 31, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult